C
NRIX icon

Covestor’s Nurix Therapeutics NRIX Stock Holding History

Covestor’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
31
+22
+244% +$375 ﹤0.01% 2251
2026
Q1 		$0 Hold
9
– – ﹤0.01% 2613
2025
Q4 		$0 Hold
9
– – ﹤0.01% 2588
2025
Q3 		$0 Hold
9
– – ﹤0.01% 2601
2025
Q2 		$0 Buy
9
+4
+80% +$43 ﹤0.01% 2573
2025
Q1 		$0 Hold
5
– – ﹤0.01% 2566
2024
Q4 		$0 Hold
5
– – ﹤0.01% 2574
2024
Q3 		$0 Sell
5
-2
-29% -$45 ﹤0.01% 2571
2024
Q2 		$0 Buy
+7
New +$109 ﹤0.01% 2584
2022
Q2 		– Sell
-13
Closed – – 2205
2022
Q1 		$0 Buy
13
+2
+18% +$36 ﹤0.01% 2320
2021
Q4 		$0 Buy
+11
New +$333 ﹤0.01% 2231

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Covestor's NRIX Position: Q2 2026 in Review

Covestor increased its Nurix Therapeutics (NRIX) stake by 244% in Q2 2026, buying an estimated $375 and bringing the position to 31 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Covestor first reported a position in NRIX in Q4 2021 and has held it in 11 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Covestor held 31 shares of Nurix Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 22 Nurix Therapeutics shares in Q2 2026, an estimated $375.
  • Nurix Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2251 holding.
  • Covestor first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.